Benzinga | Aug 5, 2020 04:59PM EDT

ACADIA Pharmaceuticals Q2 EPS $(0.27) Beats $(0.44) Estimate, Sales $110.10M Beat $103.34M Estimate; Narrows, Raises Low End Of FY20 NUPLAZID Net Sales From $420M-$450M To $430M-$450M

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.44) by 38.64 percent. This is a 28.95 percent increase over losses of $(0.38) per share from the same period last year. The company reported quarterly sales of $110.10 million which beat the analyst consensus estimate of $103.34 million by 6.54 percent. This is a 32.33 percent increase over sales of $83.20 million the same period last year.